CuraLase clinics have administered over 100,000 treatments to over 8,000 patients from 44 states and 31 countries, establishing an international reputation for exceptional patient care. Achieving over a 90% success rate, CuraLase offers a non-invasive treatment option to individuals with pain. CuraLase delivers a pathway for patients to “get their quality of life back.”
The CuraLase History
Since its founding in 2005, CuraLase has been an innovator in non-invasive Photon Therapy treatment for a multitude of painful conditions. Roger Porter, inventor and engineer, was seeking an alternative treatment for a family member’s excruciating pain from rheumatoid arthritis when he met Frank G. McArthur, MD. Dr. McArthur had previously been the Medical Director of the Health South system rehabilitation hospitals. Working together, Porter and McArthur researched and developed an innovative device and initial protocols. In December 2005, the CuraLase device was FDA cleared as a non-significant risk for the treatment of pain. The FDA rated the CL1000 with the safest classification awarded to any treatment modality. The first clinic opened in March 2006 in Myrtle Beach, South Carolina. Porter and a team of seven physicians refined the initial treatment protocols and developed new treatment protocols with great success.
CuraLase was awarded FDA clearance in 2005.
Harvard clinical trial proves PBM activates stem cells to regenerate tissue
Harvard School of Engineering and Applied Sciences (SEAS)
David J. Mooney, Praveen Arany, Ph.D.,
Harvard’s groundbreaking new research in the use of PBM to stimulate stem cells to regrow tissue is generating interest and excitement throughout the medical community.
A systematic review and meta-analysis of the effect of PBM on chemotherapy-induced oral mucositis in pediatric and young patients
Department of Hematology and Oncology, Shanghai Children’s Medical Center, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Holanda VM, Chavantes MC, Wu X, Anders.
Therapeutic PBM also reduces the average severity of oral mucositis and oral pain.
Efficacy of PMB for treatment of cancer oral mucositis
Graduation Program on Evaluation and Production of Technologies for the Brazilian National Health System, Hospital Nossa Senhora da Conceição, Porto Alegre, Rio Grande do Sul, Brazil
Anschau F, Webster J, Capra MEZ, de Azeredo da Silva ALF, Stein AT.
PBM demonstrates potential for decreasing the resolution time of OM lesions by approximately 4.21 days.
PBM in treatment of chemoradiotherapy-induced mucositis in head and neck cancer: results of a randomised, triple blind, multicentre phase III trial.
Département de Radiothérapie, Institut de Cancérologie de l’Ouest – Paul Papin, 15 rue André Boquel, Angers, France
Legouté F, Bensadoun RJ, Seegers V, Pointreau Y, Caron D, Lang P6, Prévost A, Martin L, Schick U, Morvant B, Capitain O, Calais G, Jadaud E.
PBM was well tolerated with a good safety profile, which promotes its use in clinical routine for severe OM treatment.